Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Topical Treatments for Hair Loss: FDA-Approved and Compounded Options
Description
The talk reviews topical treatments for hair loss, dividing them into FDA-approved and compounded options. Minoxidil is the only FDA-approved topical for hair loss and remains the gold standard; it is available as 5% foam or solution, with the foam causing less irritation and the solution often working better due to enhanced penetration. The speaker explains that minoxidil prolongs the anagen phase, promotes the telogen-to-anagen switch, and transforms vellus hairs into terminal hairs. Non-FDA-approved compounded options include topical finasteride, dutasteride, spironolactone, ketoconazole, clascoterone, latanoprost, and bimatoprost, many of which are used in combination with minoxidil. Finasteride and dutasteride reduce DHT by inhibiting 5-alpha reductase; topical finasteride may be comparable to oral finasteride and works best in combination regimens. Spironolactone can be compounded topically but may irritate the skin. Ketoconazole has anti-inflammatory and anti-androgen effects. Clascoterone is a promising newer option, with studies showing hair growth comparable to minoxidil and phase 3 trials underway. Latanoprost may also increase hair density. The speaker emphasizes that compounded products lack standardized recipes and quality can vary, so pharmacy expertise matters.
View moreConclusions
- Topical minoxidil is the only FDA-approved topical treatment for hair loss and remains the gold standard.
- Most other topical hair-loss therapies, including finasteride, dutasteride, spironolactone, ketoconazole, clascoterone, latanoprost, and bimatoprost, are not FDA approved and require compounding.
- Compounded topical products can be hard to evaluate because formulations and excipients are not standardized and may vary by pharmacy.
- Topical finasteride and dutasteride appear to reduce hair loss by blocking 5-alpha reductase and lowering DHT, with topical finasteride performing similarly to oral finasteride in some studies.
- Many compounded combinations seem more effective when minoxidil is included, but this also makes it difficult to know which ingredient is driving the benefit.
- Topical spironolactone may improve regrowth, especially when combined with minoxidil, but irritation is a concern.
- Topical ketoconazole may help hair loss through anti-inflammatory and anti-androgen effects, though benefits may plateau over time.
- Topical clascoterone is a promising emerging option with early evidence comparable to minoxidil and phase 3 trials underway.
- Topical latanoprost may increase hair density and prolong anagen, but evidence remains limited.
- Overall, the field suggests several potentially useful nonapproved topical options, but minoxidil remains the most established and reliable treatment.
- Abdel-Raouf H et al. A novel topical combination of minoxidil and spironolactone for androgenetic alopecia. Dermatol Ther. 2021;34(1):e14678.#10.1001/archderm.1988.01670030010005
- Pierard-Franchimont C et al. Ketoconazole shampoo: effect of long-term use on androgenetic alopecia. Dermatology 1998;196(4):474-477.#10.1159/000017954
- Cartwright M et al. A summary of in vitro, phase I, and phase II studies evaluating clascoterone. JAAD 2019;81(4):AB13.
- Blume-Peytavi U et al. Randomized double-blind placebo-controlled pilot study of latanoprost for hair growth. Journal of the American Academy of Dermatology, 2012.
- Rafi and Katz.
- Mazzarella et al.
- Caserini et al.